InsiderTrades.com logo

BXRX Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 0.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Baudax Bio Insider Trading History Chart

This chart shows the insider buying and selling history at Baudax Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Baudax Bio Share Price & Price History

Current Price: $0.02
Price Change: +0.30 (1.20%)
As of 02/29/2024 01:00 AM ET

This chart shows the closing price history over time for BXRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Baudax Bio Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2022Geraldine HenwoodCEOBuy1,200$2.55$3,060.002,427View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Baudax Bio (NASDAQ:BXRX)

9.05% of Baudax Bio stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BXRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Baudax Bio Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
7/21/2023Creative Planning45,001$53K0.0%N/A0.657%Search for SEC Filing on Google Icon
11/7/2022Virtu Financial LLC108,332$27K0.0%+428.3%0.542%Search for SEC Filing on Google Icon
11/7/2022Warberg Asset Management LLC270,000$66K0.0%+682.6%1.350%Search for SEC Filing on Google Icon
8/8/2022Walleye Capital LLC195,095$0.17M0.0%N/A3.037%Search for SEC Filing on Google Icon
5/13/2022Warberg Asset Management LLC34,500$61K0.0%N/A0.537%Search for SEC Filing on Google Icon
2/14/2022GSA Capital Partners LLP694,276$0.15M0.0%N/A0.684%Search for SEC Filing on Google Icon
1/28/2022Amplius Wealth Advisors LLC248,375$54K0.0%N/A0.245%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.1,329,684$0.75M0.0%+1.5%1.575%Search for SEC Filing on Google Icon
8/16/2021State Street Corp284,553$0.22M0.0%N/A0.337%Search for SEC Filing on Google Icon
8/16/2021Goldman Sachs Group Inc.151,323$0.12M0.0%N/A0.179%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.
Read More on Baudax Bio

Today's Range

Now: $0.02
Low: $0.02
High: $0.02

50 Day Range

MA: $0.02
Low: $0.02
High: $0.03

52 Week Range

Now: $0.02
Low: $0.01
High: $3.47

Volume

310,872 shs

Average Volume

281,029 shs

Market Capitalization

$1.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57